TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

DIA and Tufts CSDD Collaborate to Explore the Current Implementation and Perspectives on AI in Drug Development

Thursday, February 01, 2024

DIA, a global organization of life science professionals, has partnered with the Tufts Center for the Study of Drug Development (Tufts CSDD) to conduct an extensive study aimed at advancing our understanding of how artificial intelligence (AI) contributes to the entire drug development process.

This joint study is supported by 16 prominent biopharmaceutical companies and contract research organizations (CROs). The main focus of the working group will be to explore the application of AI, encompassing machine learning (ML) and natural language processing (NLP) models, across various facets of clinical operations and development. These include site identification, patient recruitment, pharmacovigilance, quality assurance, and clinical monitoring. The overarching goal is to identify the most effective utilization of AI tools in these areas.

Marwan Fathallah, President and Global Chief Executive of DIA, expressed the desire for global organizations to comprehend the practical applications of AI in drug development and optimize their investments in this technology. Recognizing that some organizations invest substantial time, money, and resources into AI without seeing the expected returns, the study aims to unveil successful implementation strategies and encourage industry-wide development to expedite the availability of promising treatments.

The working group will actively contribute to shaping the study methodology, which includes developing a landscape survey and participating in in-depth interviews to highlight real-world applications of AI. The findings will be disseminated through a peer-reviewed article.

Dr. Mary Jo Lamberti, Research Associate Professor and Director of Sponsored Research at Tufts CSDD, emphasized that the study presents a significant opportunity to benchmark AI usage across the industry. Given the maturity of AI adoption since their previous study in 2019, the focus now is on identifying the most effective and impactful approaches within clinical development.

It's worth noting that DIA and Tufts CSDD had previously collaborated in 2019 on a landscape analysis of AI usage in biopharmaceutical development. The findings from that study revealed that AI was most frequently employed in patient selection and recruitment. Additionally, a notable barrier to widespread adoption was identified in the form of a shortage of staff with the requisite skill sets.

 

Source: businesswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit